We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
The spread of COVID-19 continues to impact both our personal and professional lives. FUJIFILM Irvine Scientific implemented our Business Continuity Plans designed to address the effects of business interruption in a crisis. As part of these plans, in January we began taking extra steps to mitigate risks from the spread of coronavirus (SARS-CoV-2). FUJIFILM Irvine Scientific is continuously monitoring the situation to take all available actions to continue delivering products and services to our customers.
First, we want to assure you that our global sites are open and continuing to operate as expected. We recognize our products are essential raw materials for life saving therapies, vaccines, and diagnostics and are committed to take whatever actions we can to continue delivering products and services to our customers.
We have taken steps to ensure the safety of our employees such as implementing policies to maintain social distance, and following CDC and WHO guidelines on how to prevent infection. We are working closely with our supply chain, logistics and business partners to minimize risks of disruption.
We understand the volatility of today’s markets is creating anxiety. FUJIFILM Irvine Scientific is secure and backed by the strength of FUJIFILM Holdings, a Fortune 500 company. FUJIFILM brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to various fields including, healthcare, graphic systems, highly functional materials, optical devices, digital imaging, and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic, and imaging technologies. FUJIFILM has global revenues of $22 billion.1
We will continue to monitor the situation, follow guidelines from official health authorities, and take appropriate steps to protect supply.
Please send any questions regarding this situation to fisiqasupport@fujifilm.com.
Sincerely,
Yutaka Yamaguchi
President and CEO
1For the year ended March 31, 2019, the company had global revenues of $22 billion at an exchange rate of 111 yen to the dollar.
With the collective goal of enhancing society through innovation, the Fujifilm family is committed to leveraging its resources, talent and technologies to support global efforts to counter the COVID-19 pandemic.
LEARN MOREFAQ
A. Yes. Our Business Continuity Plans (BCP) are designed to address the effects of business interruption in any crisis. We enacted our BCP plans in January. For a summary of the actions taken please email us at fisiqasupport@fujifilm.com for a copy of our COVID-19 Response Summary.
A. We have manufacturing facilities in Santa Ana, CA, USA (primary location) and Toda, Japan. Our corporate headquarters is in California. We have regional commercial offices in Ireland, China, Italy, and the Netherlands.
A. There is no disruption in supply at the moment.
A. Yes. We implemented travel restrictions for employees that banned air travel as early as February.
A. We have taken steps to ensure the safety of our employees such as implementing policies to maintain social distance, and following CDC and WHO guidelines on how to prevent infection. Employees who can, are working remotely. Those required to be on site have been split into shifts or discrete workgroups to minimize chance of infection.
A. Travel restrictions for our employees are in place but our technical experts are still available to offer assistance via phone or video conferencing. They can be contacted at irvinescihelp@fujifilm.com.
A. We are experiencing some challenges such as canceled routes, airport shutdowns, and related logistical issues that have required increased monitoring and adjustments as issues arise. By working closely with our logistic partners we have been able to adjust and have no problems with deliveries to-date, or with upcoming shipments. We anticipate this situation will continue to change rapidly. Our Customer Service department can provide updates on your order.
A. FUJIFILM Irvine Scientific provides critical raw materials which are essential to Pharmaceutical companies producing lifesaving medical therapies, vaccines, and medical diagnostics. As such we are allowed to continue to operate as an Essential Business for Healthcare infrastructure.
A. Yes. Our Account Managers and Customer Service Department have been set up to work remotely. Please order products following your usual process.
A. This dedicated COVID-19 web page and FAQs will be updated with changes to our situation or status. Notification of a significant change to our situation will be sent to affected customers through email.
